methotrexate has been researched along with Minimal Disease, Residual in 73 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (16.44) | 18.2507 |
| 2000's | 22 (30.14) | 29.6817 |
| 2010's | 36 (49.32) | 24.3611 |
| 2020's | 3 (4.11) | 2.80 |
| Authors | Studies |
|---|---|
| Campana, D; Cheng, C; Coustan-Smith, E; Lins, MM; Lucena-Silva, N; Pedrosa, A; Pedrosa, F; Pedrosa, M; Ramos, AML; Ribeiro, RC; Rivera, GK; Vinhas, E; Zhou, Y | 1 |
| Biffi, A; Buffardi, S; Buldini, B; Carraro, E; Cavallaro, E; Cellini, M; D'Amore, ESG; Damanti, CC; Gallingani, I; Lovisa, F; Micalizzi, C; Mussolin, L; Piglione, M; Pillon, M; Sala, A; Santoro, N; Vinti, L | 1 |
| Candoni, A; Canichella, M; Cavalli, M; Chiaretti, S; Conter, V; D'Aloisio, M; De Propris, MS; Elia, L; Fazi, P; Foà, R; Guarini, A; Luppi, M; Martino, B; Messina, M; Moleti, ML; Piciocchi, A; Starza, ID; Testi, AM; Vignetti, M; Vitale, A | 1 |
| Cai, X; Chen, X; Li, C; Liang, Y; Wang, H; Xia, Z | 1 |
| Abrahamsson, J; Åsberg, A; Bernell, P; Birgens, H; Griškevičius, L; Hallböök, H; Heyman, M; Holm, MS; Hulegårdh, E; Jónsson, OG; Klausen, TW; Marquart, HV; Nielsen, OJ; Quist-Paulsen, P; Schmiegelow, K; Taskinen, M; Toft, N; Vaitkeviciene, G; Vettenranta, K | 1 |
| Langer, T; Möricke, A; Paulides, M; Radtke, S; Renner, B; Schrappe, M; Stanulla, M; Zimmermann, M; Zolk, O | 1 |
| Bartram, CR; Koehler, R | 1 |
| Eckert, C; Henze, G; v Stackelberg, A | 1 |
| Karawajew, L; Ludwig, WD; Möricke, A; Ratei, R; Schabath, R; Schrappe, M; Zimmermann, M | 1 |
| Burger, JA; Challagundla, P; Champlin, RE; Cortes, JE; Estrov, Z; Faderl, S; Ferrajoli, A; Garris, R; Huang, X; Jorgensen, JL; Kantarjian, HM; Kebriaei, P; Luthra, R; O'Brien, S; Ravandi, F; Thomas, DA; Wang, SA; Wen, S | 1 |
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Tong, H; Tong, Y | 1 |
| Heitplatz, B; Müller, KM | 1 |
| Chen, Y; Ding, M; Huang, S; Jiang, W; Li, Q; Luo, X; Qi, H; Wang, Z; Xiao, X; Zhang, H; Zhang, X; Zheng, Y | 1 |
| Goulden, N; Hancock, J; Hough, R; Mitchell, C; Moorman, AV; Rowntree, C; Vora, A; Wade, R | 1 |
| Ribeiro, RC; Rivera, GK | 1 |
| Aricò, M; Barisone, E; Basso, G; Cazzaniga, G; Conter, V; Fabbri, G; Fagioli, F; Giraldi, E; Paganin, M; Polato, K; Valsecchi, MG | 1 |
| Koh, K | 1 |
| Jansen, TL; Lamers-Karnebeek, F; van Ingen, IL | 1 |
| Bhojwani, D; Bowman, WP; Campana, D; Cheng, C; Coustan-Smith, E; Downing, JR; Evans, WE; Gruber, TA; Inaba, H; Jeha, S; Leung, WH; Pei, D; Pui, CH; Relling, MV; Ribeiro, RC; Rubnitz, JE; Sandlund, JT | 1 |
| Borowitz, MJ; Carroll, AJ; Carroll, WL; Dai, Y; Devidas, M; Gastier-Foster, JM; Heerema, NA; Hunger, SP; Larsen, E; Loh, ML; Nachman, JB; Raetz, EA; Salzer, WL; Willman, CL; Winick, NJ; Wood, BL | 1 |
| Bago-Horvath, Z; Bartsch, R; Bergen, E; Dubsky, P; Exner, R; Gnant, M; Jakesz, R; Mittlböck, M; Ott, J; Panhofer, P; Promberger, R; Rudas, M; Seemann, R; Singer, C; Steger, G | 1 |
| Burger, JA; Champlin, R; Cortes, JE; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Garris, R; Huang, X; Jabbour, E; Kantarjian, HM; Kebriaei, P; McCue, DA; O'Brien, SM; Ravandi, F; Rytting, ME; Thomas, DM; Verstovsek, S; Wierda, WG | 1 |
| Goulden, N; Hough, R; Mitchell, C; Moorman, A; Rowntree, C; Vora, A; Wade, R | 1 |
| Aricò, M; Attarbaschi, A; Barisone, E; Bartram, CR; Basso, G; Beier, R; Biondi, A; Caruso, R; Cazzaniga, G; Conter, V; Greiner, J; Harbott, J; Kremens, B; Kulozik, AE; Lo Nigro, L; Locatelli, F; Mann, G; Möricke, A; Niggli, F; Parasole, R; Ratei, R; Rössig, C; Schrappe, M; Silvestri, D; Stanulla, M; Valsecchi, MG; von Stackelberg, A; Zimmermann, M | 1 |
| Antoni, D; Coca, A; Entz-Werlé, N; Jannier, S; Jarnet, D; Kehrli, P; Lutz, P; Meyer, P; Niederst, C; Noël, G; Spiegel, A; Vigneron, C | 1 |
| Cortes, JE; Garcia-Manero, G; Garris, R; Issa, GC; Jabbour, E; Kantarjian, H; Luthra, R; O'Brien, SM; Patel, K; Ravandi, F; Sasaki, K; Short, NJ; Thomas, D | 1 |
| Coleman, RE; Gillett, S; Hancock, BW; Hills, A; Ireson, J; Singh, K; Tidy, JA; Winter, MC | 1 |
| Balzarotti, M; Cabrera, ME; Ceriani, L; Chiappella, A; Cunningham, D; Ferreri, AJ; Giovanella, L; Gospodarowicz, MK; Guarini, A; Johnson, PW; Martelli, M; Ricardi, U; Stelitano, C; Zinzani, PL; Zucca, E | 1 |
| Barr, PM; Bernstein, SH; Blum, KA; Cashen, AF; Chen, RW; Cheson, BD; Constine, L; Faham, M; Fenske, TS; Fisher, RI; Forman, SJ; Friedberg, JW; Kahl, BS; Kahwash, S; Leblanc, M; Leonard, JP; Li, H; Phillips, T; Rimsza, LM; Shea, TC; Smith, SM; Wilkins, J | 1 |
| Campana, D; Pui, CH | 1 |
| Basso, G; Biondi, A; Fabbri, G; Locatelli, F; Paganin, M; Polato, K; Rizzari, C; Zecca, M | 1 |
| Borowitz, MJ; Bowman, WP; Camitta, BM; Campana, D; Cao, X; Carroll, WL; Cheng, C; Davies, SM; Devidas, M; Downing, JR; Evans, WE; Fan, Y; French, D; Hunger, SP; Neale, G; Pei, D; Pounds, SB; Pui, CH; Relling, MV; Treviño, LR; Willman, CL; Yang, JJ; Yang, W | 1 |
| Eden, T; Hill, F; Hussain, A; Mitchell, C; Richards, S; Simpson, J; Taylor, GM; Wade, R | 1 |
| Avril, N; Avril-Sassen, S; Dose-Schwarz, J; Jänicke, F; Lebeau, A; Mahner, S; Schwaiger, M; Tiling, R; Untch, M; Weber, C | 1 |
| Meeker, ND; Schiffman, JD; Yang, JJ | 1 |
| Balter, R; Barra, S; Bertin, D; Biassoni, V; Cama, A; Casali, C; Collini, P; Di Rocco, C; Fidani, P; Gandola, L; Garrè, ML; Genitori, L; Giangaspero, F; Mascarin, M; Massimino, M; Milanaccio, C; Milano, GM; Modena, P; Nozza, P; Peretta, P; Potepan, P; Sardi, I; Scarzello, G; Tamburrini, G; Viscardi, E | 1 |
| Blach, L; Borowitz, MJ; Bowman, WP; Camitta, BM; Carroll, AJ; Carroll, WL; Devidas, M; Hunger, SP; Larsen, EL; Linda, SB; Pullen, DJ; Shuster, J; Willman, CL; Winick, N | 1 |
| Bari, M; Ciruelos, E; De Benedictis, E; Dittrich, C; Gaion, F; Gomez, P; Lluch, A; Luca, G; Mansutti, M; Morandi, P; Pavesi, L; Semiglazov, V; Valagussa, P; Zamagni, C; Zambetti, M | 1 |
| Ayari, S; Chevallier, P; Delaunay, J; Dumas, PY; Eveillard, M; Guillaume, T; Leguay, T; Lippert, E; Mohty, M; Pigneux, A; Robillard, N | 1 |
| Catalano, PJ; Halasz, LM; Jacene, HA; Lacasce, A; Mauch, PM; Ng, AK; Van den Abbeele, AD | 1 |
| Benesch, M; Deinlein, F; Faldum, A; Friedrich, C; Gerber, NU; Kortmann, RD; Kuehl, J; Kwiecien, R; Ottensmeier, H; Pietsch, T; Rutkowski, S; von Bueren, AO; von Hoff, K; Warmuth-Metz, M | 1 |
| Goulden, N; Hancock, J; Hough, R; Mitchell, C; Richards, S; Rowntree, C; Vora, A; Wade, R | 1 |
| Algara, P; Díaz, MA; Madero, L; Martínez, P; Ramírez, M; Tutor, O | 1 |
| Aricò, M; Basso, G; Biondi, A; Cazzaniga, G; Di Martino, D; Lanciotti, M; Masera, G; Micalizzi, C; Rossi, V; Valsecchi, MG | 1 |
| Clausen, N; Jonmundsson, GK; Madsen, HO; Nyvold, C; Ryder, LP; Schmiegelow, K; Seyfarth, J; Wesenberg, F | 1 |
| Ahmed, S; Aitken, M; Coleman, RE; Everard, J; Hancock, BW; Khan, F | 1 |
| Akioka, T; Hanafusa, T; Hara, S; Oka, S; Tsuji, M; Yamano, T; Yokote, T | 1 |
| Cho, SG; Eom, KS; Kim, CC; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Leporrier, M; Marcelli, C; Mittre, H | 1 |
| de Anta, JM; Freire, R; Mayol, X; Pérez-Castro, AJ | 1 |
| Li, JG; Wan, XR; Xiang, Y; Yang, JJ; Yang, XY | 1 |
| Brackstone, M; Chambers, AF; Townson, JL | 1 |
| Culine, S; Droz, JP; Duvillard, P; Kattan, J; Lhomme, C; Michel, G | 1 |
| Eaton, M; Humeniuk, V; Kent, AL; Marshall, N | 1 |
| Bartolucci, AA; Gordon, DS; Martelo, O; Omura, GA; Vogler, WR | 1 |
| Adler, DD; Cody, RL; Helvie, MA; Joynt, LK; Merajver, SD; Pierce, LJ | 1 |
| Brugger, SA; Dieckmann, KU; Fischer, G; Geissler, K; Greinix, HT; Haas, O; Hinterberger, W; Hocker, P; Jager, U; Kalhs, P; Keil, F; Lechner, K; Linkesch, W; Mannhalter, C; Reiter, E; Schneider, B; Schwarzinger, I | 1 |
| Bradstock, K; Brisco, J; Enno, A; Hughes, E; McCaul, K; Morley, AA; Neoh, SH; Sykes, PJ; Szer, J | 1 |
| Jekunen, AP; Kairemo, KJ; Kajanti, MJ; Lehtonen, HP | 1 |
| Babini, L; Barbieri, E; Battista, G; Bendandi, M; Canini, R; Fanti, S; Frezza, G; Gherlinzoni, F; Gozzetti, A; Merla, E; Monetti, N; Pisi, P; Rimondi, MR; Tura, S; Zinzani, PL; Zompatori, M | 1 |
| Dibenedetto, SP; Lo Nigro, L; Mayer, SP; Rovera, G; Schilirò, G | 1 |
| Okamoto, M | 1 |
| Falletta, V; Pavone, C; Pavone-Macaluso, M; Piazza, F; Serretta, V; Vasile, P | 1 |
| Algara, P; Díaz, MA; Madero, L; Martínez, P; Tutor-Ureta, O | 1 |
| Fasching, K; Gadner, H; Panzer, S; Panzer-Grümayer, ER; Schneider, M | 1 |
| Bash, R; Hosler, GA; Scheuermann, RH | 1 |
| Hochberg, FH; Kim, L; Shaeffer, P | 1 |
| Behm, FG; Boyett, JM; Campana, D; Coustan-Smith, E; Hancock, ML; Pui, CH; Raimondi, SC; Ribeiro, RC; Rivera, GK; Rubnitz, JE; Sancho, J; Sandlund, JT | 1 |
| Chang, SP; Su, WH; Wang, PH | 1 |
| Benedetti, F; Bordignon, C; Bregni, M; Ciceri, F; Corradini, P; Dodero, A; Falda, M; Gianni, AM; Ladetto, M; Lucesole, M; Olivieri, A; Pileri, A; Rambaldi, A; Sajeva, MR; Tarella, C; Tresoldi, M; Voena, C; Zallio, F | 1 |
| Botsonis, A; Moschovi, M; Papadopoulou, AL; Tsangaris, GT; Tzortzatou-Stathopoulou, F | 1 |
| Estlin, EJ | 1 |
| Boardman, CH; Dowdy, SC; Hartmann, LC; Long, HJ; Podratz, KC; Wilson, TO | 1 |
8 review(s) available for methotrexate and Minimal Disease, Residual
| Article | Year |
|---|---|
Improving treatment of children with acute lymphoblastic leukemia in developing countries through technology sharing, collaboration and partnerships.
Topics: Antimetabolites, Antineoplastic; Child; Developing Countries; Humans; Methotrexate; Neoplasm, Residual; Partnership Practice; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2014 |
[Current treatment of pediatric acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child, Preschool; Clinical Trials as Topic; Cytarabine; Dexamethasone; Drug Discovery; Humans; Imatinib Mesylate; Induction Chemotherapy; Mercaptopurine; Methotrexate; Molecular Targeted Therapy; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines | 2014 |
Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Administration Schedule; Humans; Methotrexate; Neoplasm, Residual; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alpha; Withholding Treatment | 2014 |
Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Cyclophosphamide; Daunorubicin; Humans; Induction Chemotherapy; Male; Methotrexate; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Vincristine | 2017 |
Pharmacogenomics of pediatric acute lymphoblastic leukemia.
Topics: Child; Cytochrome P-450 CYP3A; Glucocorticoids; Humans; Methotrexate; Methyltransferases; Neoplasm, Residual; Pharmacogenetics; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vincristine | 2010 |
Treatment of olfactory neuroblastoma. A report of 11 cases.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Esthesioneuroblastoma, Olfactory; Female; Follow-Up Studies; Humans; Leucovorin; Male; Methotrexate; Middle Aged; Nasal Cavity; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Nose Neoplasms; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Survival Rate | 1996 |
Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Marrow Transplantation; Burkitt Lymphoma; Child; Child, Preschool; Combined Modality Therapy; Daunorubicin; Disease-Free Survival; Female; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; Immunoglobulin Heavy Chains; Infant; Leukemia-Lymphoma, Adult T-Cell; Life Tables; Male; Methotrexate; Neoplasm, Residual; Polymerase Chain Reaction; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Remission Induction; Retrospective Studies; Risk; Survival Analysis; Survival Rate; Treatment Outcome; Vincristine | 2001 |
Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine.
Topics: Antineoplastic Agents; Child; Humans; Mercaptopurine; Methotrexate; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thioguanine | 2001 |
21 trial(s) available for methotrexate and Minimal Disease, Residual
| Article | Year |
|---|---|
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Kaplan-Meier Estimate; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Treatment Outcome; Vincristine; Young Adult | 2021 |
[Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Genetic Markers; Humans; Mercaptopurine; Methotrexate; Neoplasm, Residual; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Prospective Studies; Vincristine | 2013 |
Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cell Lineage; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; Immunophenotyping; Infant; Leukemia, Biphenotypic, Acute; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Survival Analysis; Vincristine | 2013 |
Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Infant; Male; Mercaptopurine; Methotrexate; Mucositis; Neoplasm, Residual; Pancreatitis; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Risk Assessment; Stomatitis; Survival Rate; Vincristine | 2014 |
Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Humans; Infant; Italy; Male; Methotrexate; Neoplasm Recurrence, Local; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Real-Time Polymerase Chain Reaction; Remission Induction; Steroids; Treatment Outcome | 2014 |
Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Infant; Male; Methotrexate; Neoplasm Recurrence, Local; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prospective Studies; Remission Induction; Risk Factors; United States; Vincristine | 2015 |
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.
Topics: Antineoplastic Agents; Asparaginase; Child; Child, Preschool; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Flow Cytometry; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leucovorin; Maintenance Chemotherapy; Male; Methotrexate; Neoplasm, Residual; Polyethylene Glycols; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Proportional Hazards Models; Risk Factors | 2015 |
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Analysis; Treatment Outcome; Vincristine; Young Adult | 2015 |
Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Daunorubicin; Dexamethasone; Female; Humans; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Assessment; Survival Analysis; Treatment Outcome; Vincristine; Young Adult | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Dexamethasone; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Male; Methotrexate; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Proportional Hazards Models; Remission Induction; Treatment Outcome | 2016 |
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Outcome; Vincristine; Young Adult | 2017 |
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Mercaptopurine; Methotrexate; Multivariate Analysis; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Prednisone; Prognosis; Prospective Studies; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 2008 |
Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Humans; Magnetic Resonance Imaging; Mammography; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Ultrasonography, Mammary | 2010 |
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Female; Humans; Infant; Kaplan-Meier Estimate; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Risk Factors; Thioguanine; Treatment Outcome; Vincristine | 2011 |
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Leukopenia; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Neutropenia; Paclitaxel; Receptors, Estrogen; Treatment Outcome | 2012 |
Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Humans; Infant; Ireland; Male; Methotrexate; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Treatment Outcome; United Kingdom; Vincristine | 2013 |
The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Female; Humans; Idarubicin; Kinetics; Leukemia, Promyelocytic, Acute; Life Tables; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Survival Analysis; Tretinoin | 2006 |
Late intensification therapy in adult acute lymphoid leukemia: long-term follow-up of the Southeastern Cancer Study Group experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Life Tables; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Prospective Studies; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; United States; Vincristine | 1994 |
Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Marrow Transplantation; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Humans; Mercaptopurine; Methotrexate; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Survival Analysis; Treatment Outcome; Vincristine | 1996 |
Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Gallium Radioisotopes; Hodgkin Disease; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Mediastinal Neoplasms; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Prednisone; Radioimmunodetection; Radiotherapy; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vincristine | 1996 |
[Long-term follow up of aggressive lymphoma patients treated with CAMBO-VIP--clinical significance of a residual mass after otherwise successful chemotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Time Factors; Vincristine | 1998 |
44 other study(ies) available for methotrexate and Minimal Disease, Residual
| Article | Year |
|---|---|
Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infant; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Survival Rate; Vincristine | 2020 |
Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH-97 protocol with/without anti-CD20 administration.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Infant; Infant, Newborn; Lymphoma, B-Cell; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Prednisone; Retrospective Studies; Vincristine | 2020 |
Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Asparaginase; Cohort Studies; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Maintenance Chemotherapy; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Retrospective Studies; Risk; Time Factors; Treatment Outcome; Vincristine | 2019 |
Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytogenetic Analysis; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Male; Medication Adherence; Methotrexate; Middle Aged; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Registries; Treatment Outcome; Vincristine; Young Adult | 2013 |
Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Child; Child, Preschool; Cohort Studies; Female; Follow-Up Studies; Germ-Line Mutation; Humans; Infant; Liver-Specific Organic Anion Transporter 1; Male; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Staging; Neoplasm, Residual; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Reduced Folate Carrier Protein; Stomatitis; Survival Rate; Thymidylate Synthase; Tissue Distribution; Treatment Outcome | 2013 |
ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Europe; Hematopoietic Stem Cell Transplantation; Humans; Mercaptopurine; Methotrexate; Multicenter Studies as Topic; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Retreatment; Survival Rate; Vincristine | 2013 |
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Flow Cytometry; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoglobulin Heavy Chains; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Thiazoles; Vincristine; Young Adult | 2013 |
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Dexamethasone; Drug Evaluation; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2014 |
[Atypical tumor regression].
Topics: Adalimumab; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Esophagus; Gastrectomy; Humans; Long-Term Care; Male; Methotrexate; Microscopy, Electron; Neoplasm Regression, Spontaneous; Neoplasm, Residual | 2013 |
Methotrexate-loaded PLGA nanobubbles for ultrasound imaging and Synergistic Targeted therapy of residual tumor during HIFU ablation.
Topics: Animals; Cell Line, Tumor; Contrast Media; Diagnostic Imaging; Female; High-Intensity Focused Ultrasound Ablation; Humans; Lactic Acid; Methotrexate; Mice; Mice, Inbred BALB C; Mice, Nude; Microbubbles; Neoplasm, Residual; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2014 |
Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Retrospective Studies | 2015 |
[Pediatric medulloblastoma: Retrospective series of 52 patients].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; France; Humans; Infant; Male; Medulloblastoma; Methotrexate; Neoplasm, Residual; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Vincristine | 2016 |
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Infant; Male; Methotrexate; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Vincristine | 2016 |
Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.
Topics: Adult; Antineoplastic Agents; Carboplatin; Chorionic Gonadotropin; Dactinomycin; Drug Resistance, Neoplasm; Female; Gestational Trophoblastic Disease; Humans; Methotrexate; Neoplasm, Residual; Pregnancy; Retrospective Studies; Risk Assessment; Risk Factors; Uterine Neoplasms; Young Adult | 2016 |
Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Immunotherapy; Leucovorin; Liver; Lymphoma, B-Cell; Male; Mediastinal Neoplasms; Methotrexate; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Prednisone; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Conformal; Recurrence; Rituximab; Statistics, Nonparametric; Vincristine; Young Adult | 2017 |
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Etoposide; Female; Flow Cytometry; Follow-Up Studies; Genotype; Germ-Line Mutation; Humans; Infant; Linear Models; Linkage Disequilibrium; Male; Methotrexate; Neoplasm, Residual; Odds Ratio; Phenotype; Polymorphism, Single Nucleotide; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Risk Assessment; Risk Factors | 2009 |
Relationship between HLA-DP supertype and survival in childhood acute lymphoblastic leukaemia: evidence for selective loss of immunological control of residual disease?
Topics: Adolescent; Biomarkers, Tumor; Chi-Square Distribution; Child; Child, Preschool; Disease-Free Survival; Female; Genetic Predisposition to Disease; Genotype; HLA-DP Antigens; HLA-DP beta-Chains; Humans; Immunosuppressive Agents; Infant; Kaplan-Meier Estimate; Male; Methotrexate; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Randomized Controlled Trials as Topic; Statistics, Nonparametric; Treatment Outcome | 2009 |
Infant ependymoma in a 10-year AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) experience with omitted or deferred radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Ependymoma; Etoposide; Female; Humans; Infant; Infratentorial Neoplasms; Italy; Male; Methotrexate; Neoplasm, Residual; Supratentorial Neoplasms; Treatment Outcome; Vincristine | 2011 |
Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: a pilot series.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Pilot Projects; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Risk Factors; Rituximab; Salvage Therapy; Survival Rate; Vincristine; Young Adult | 2012 |
Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Prednisone; Radiopharmaceuticals; Radiotherapy Dosage; Retrospective Studies; Rituximab; Treatment Failure; Vincristine; Young Adult | 2012 |
Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemoradiotherapy; Child, Preschool; Cranial Irradiation; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Male; Methotrexate; Neoplasm Grading; Neoplasm, Residual; Neuroectodermal Tumors, Primitive; Neuropsychological Tests; Pineal Gland; Pinealoma; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Vincristine | 2013 |
Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclin-Dependent Kinase Inhibitor p16; Cyclophosphamide; Cytarabine; Drug Resistance, Neoplasm; Female; Gene Deletion; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Genes, p16; Humans; Infant; Life Tables; Loss of Heterozygosity; Male; Mercaptopurine; Methotrexate; Microsatellite Repeats; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome; Vincristine | 2002 |
Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Neoplasm, Residual; Prednisone; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2002 |
Post-induction residual disease in translocation t(12;21)-positive childhood ALL.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 21; Core Binding Factor Alpha 2 Subunit; DNA Primers; Doxorubicin; Female; Humans; Immunophenotyping; Infant; Male; Methotrexate; Neoplasm, Residual; Oncogene Proteins, Fusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Translocation, Genetic; Vincristine | 2003 |
Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Female; Gestational Trophoblastic Disease; Humans; Leucovorin; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Pregnancy; Treatment Outcome; Vitamin B Complex | 2003 |
[Graft-versus-ATLL effect induced by abrupt discontinuation of immunosuppression following allogeneic bone marrow transplantation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Cyclosporine; DNA, Viral; Doxorubicin; Graft vs Leukemia Effect; Human T-lymphotropic virus 1; Humans; Immunosuppression Therapy; Leukemia-Lymphoma, Adult T-Cell; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Prednisone; Remission Induction; Vincristine | 2005 |
Infliximab in chronic myelogenous leukemia.
Topics: Antibodies, Monoclonal; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Infliximab; Injections, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2007 |
The DNA damage checkpoint is activated during residual tumour cell survival to methotrexate treatment as an initial step of acquired drug resistance.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Cycle Proteins; Cell Survival; Checkpoint Kinase 1; DNA Damage; Drug Resistance, Neoplasm; Histones; HT29 Cells; Humans; Methotrexate; Models, Biological; Neoplasm, Residual; Phosphorylation; Protein Kinases | 2006 |
[Outcome of gestational trophoblastic neoplasia patients with residual lung tumor after completion of treatment].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chorionic Gonadotropin, beta Subunit, Human; Female; Fluorouracil; Gestational Trophoblastic Disease; Humans; Lung Neoplasms; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Pregnancy; Prognosis; Retrospective Studies | 2007 |
Tumour dormancy in breast cancer: an update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Neoplasm, Residual; Recurrence; Time Factors | 2007 |
Long-term results of two VAB-like regimens (vinblastine + actinomycin-D + bleomycin + cyclophosphamide + cisplatin) in malignant germ cell tumours of the ovary.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Cisplatin; Cyclophosphamide; Dactinomycin; Female; Germinoma; Humans; Methotrexate; Neoplasm Recurrence, Local; Neoplasm, Residual; Ovarian Neoplasms; Salvage Therapy; Vinblastine; Vincristine | 1994 |
Locally advanced breast cancer: is surgery warranted following chemotherapy?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Node Excision; Mastectomy, Simple; Menopause; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Postoperative Care; Premenopause; Radiotherapy Dosage; Retrospective Studies; Survival Rate | 1995 |
Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Estrogens, Conjugated (USP); Female; Fluorouracil; Humans; Mammography; Methotrexate; Middle Aged; Neoplasm, Residual; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Tamoxifen | 1996 |
Long-term leukemia-free survival after allogeneic marrow transplantation in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Histocompatibility; Humans; Leukemia, Myeloid; Life Tables; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Remission Induction; Salvage Therapy; Survival Rate; Transplantation, Homologous; Whole-Body Irradiation | 1996 |
Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Blotting, Southern; Bone Marrow; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; DNA, Neoplasm; Evaluation Studies as Topic; Female; Fluorometry; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Immunophenotyping; Infant; Italy; Leucovorin; Leukemia-Lymphoma, Adult T-Cell; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Neoplastic Stem Cells; Nucleic Acid Hybridization; Polymerase Chain Reaction; Prednisone; Prognosis; Prospective Studies; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Sensitivity and Specificity; Treatment Outcome; Vincristine | 1997 |
[Conservative treatment of locally advanced bladder carcinoma: neoadjuvant chemotherapy, TUR and radiotherapy. Results in 40 patients].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Evaluation Studies as Topic; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm, Residual; Preoperative Care; Radiotherapy, Adjuvant; Remission Induction; Urinary Bladder Neoplasms; Vinblastine | 1998 |
[The presence of minimal residual disease during induction therapy is a reliable factor for the prognosis of recurrence in children with standard-risk B-cell precursor acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Cyclophosphamide; Cytarabine; DNA Primers; Genes, T-Cell Receptor delta; Humans; Mercaptopurine; Methotrexate; Molecular Sequence Data; Neoplasm, Residual; Polymerase Chain Reaction; Prednisone; Prognosis; Recurrence; Retrospective Studies; Risk Factors; Sensitivity and Specificity; Vincristine | 1999 |
Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Gene Rearrangement; Humans; Infant; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Risk; Time Factors; Treatment Outcome; Vincristine | 2000 |
Kinetics of early therapeutic response as measured by quantitative PCR predicts survival in a murine xenograft model of human T cell acute lymphoblastic leukemia.
Topics: Animals; Antineoplastic Agents; Calibration; Cell Cycle; Cyclophosphamide; Cytarabine; DNA, Neoplasm; Doxorubicin; Drug Evaluation; Etoposide; Female; Flow Cytometry; Humans; Leukemia-Lymphoma, Adult T-Cell; Methotrexate; Mice; Mice, SCID; Neoplasm Transplantation; Neoplasm, Residual; Polymerase Chain Reaction; Prognosis; Reference Standards; Risk Assessment; Specific Pathogen-Free Organisms; Survival Analysis; Transplantation, Heterologous; Tumor Cells, Cultured; Vincristine | 2000 |
White-matter abnormalities in unirradiated patients cured of primary central nervous system lymphoma.
Topics: Aged; Brain; Brain Neoplasms; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Treatment Outcome | 2000 |
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Etoposide; Female; Flow Cytometry; Humans; Hydrocortisone; Immunophenotyping; Infant; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Neoplastic Cells, Circulating; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Prospective Studies; Remission Induction; Treatment Outcome; Vincristine | 2000 |
Successful treatment of a persistent mole with myometrial invasion by direct injection of methotrexate.
Topics: Adult; Antimetabolites, Antineoplastic; Chorionic Gonadotropin, beta Subunit, Human; Female; Humans; Hydatidiform Mole; Injections, Intralesional; Methotrexate; Myometrium; Neoplasm Invasiveness; Neoplasm, Residual; Pregnancy; Ultrasonography; Uterine Neoplasms; Vacuum Curettage | 2001 |
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Recurrence; Remission Induction; Survival Rate; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubicin; Female; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Neutropenia; Retrospective Studies; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine | 2002 |